Structure-based scaffold hopping reveals strategies to overcome oncogenic KIT and PDGFRA mutation-driven drug-resistance in GIST.
Summary
This study investigates strategies to overcome drug resistance in gastrointestinal stromal tumors (GIST) driven by oncogenic KIT and PDGFRA mutations. Current tyrosine kinase inhibitors (TKIs) face limitations due to off-target toxicities and resistance mutations. Researchers employed a structure-based scaffold-hopping approach to design novel selective inhibitors. Their structure-activity relationship studies and 14 co-crystal structures, including one for PDGFRA-G680R, helped define key molecular interactions underlying resistance and selectivity. The developed 6,7-quinazoline-based inhibitors demonstrate high potency against clinically relevant KIT/PDGFRA mutations and effectively suppress downstream signaling.
Analysis
From a biomolecular perspective, this research represents a significant advance in pharmacology by employing a structure-based scaffold-hopping strategy to design kinase inhibitors. The study identified novel 6,7-quinazoline-based inhibitors that specifically target KIT and PDGFRA resistance mutations. The use of 14 co-crystal structures, including that of PDGFRA-G680R, allowed for the precise deciphering of molecular interactions underlying resistance and inhibitor selectivity, providing selective chemical tools to investigate these mechanisms. Clinically, this discovery has major translational impact by directly addressing the challenges of TKI resistance and off-target toxicities in GIST. By developing more selective and potent inhibitors against resistance mutations like PDGFRA-G680R, this approach could potentially improve treatment efficacy and reduce side effects for patients with resistant GIST. While an early-stage discovery, it would ultimately justify extensive preclinical testing followed by Phase I/II trials, with a potential clinical impact in 5+ years.